New data on the pharmacology of heparin and low molecular weight heparins

Drugs

Volumn 52, Issue SUPPL. 7, 1996, Pages 8-15

  Samama, M M ^a,b   Bara, L ^a   Gouin Thibault, I ^a  

^a Laboratoire Central d'Hematologie   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; DALTEPARIN; ENOXAPARIN; HEPARIN; LIPID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PROTHROMBIN; REVIPARIN; TINZAPARIN;

BLEEDING; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; HIP SURGERY; HUMAN; LIPID BLOOD LEVEL; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; RISK; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 0030462546     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600527-00004     Document Type: Conference Paper

References (24)

1. Fareed J, Walenga JM, Hoppensteadt D, et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci 1989; 556: 333-53
2. Linhardt RJ, Loganathan D, Al-Hakim A. Oligosaccharide mapping of low molecular weight heparins: structure and activity difference. J Med Chem 1990; 33: 1639-45
3. Bendetowicz AV, Pacaud E, Beguin S, et al. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin). Thromb Haemost 1992; 67 (5): 556-62
4. Hemker HC. Discussion. Avoiding thromboembolism and its sequelae: the role of reviparine sodium, LMWHs are not equal. Kakkar VV, Samama MM, editors. Thromb Res 1996; 81 Suppl. 2: S36-8
5. Bara L, Bloch MF, Zitoun D, et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52
6. Gerotziafas GT, Bara L, Bloch MF, et al. Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. Thromb Res 1996; 81: 491-6
7. Iverson N, Abildgaard U. Role of antithrombin and tissue factor pathway inhibitor in the control of thrombosis and mediation of heparin action. Clin Appl Thrombosis/Hemostasis 1996; 2 (1): 1-6
8. Eriksson BI, Söderberg K, Widlund L, et al. A comparative study of three low molecular weight heparins (LMWHs) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73 (3): 398-401
9. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73 (4): 630-40
10. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low molecular weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92: 2819-24
11. Dawes J. Interactions of heparins in the vascular environment. Haemostasis 1993; 23 (1): 212-9
12. Young E, Wells P, Holoway S, et al. Ex vivo and in vitro evidence that low molecular weight heparin exhibits less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71 (3): 292-300
13. Lane DA, Denton J, Flynn AM, et al. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-32
14. Carrie D, Caranobe C, Boneu B. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit. Br J Haematol 1993; 83: 622-6
15. Millet J, Theveniaux J, Tachon G, et al. The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique. In press, 1996
16. Shen ZX, Li JM, Wang ZY, et al. Thrombocytopoietic effect of heparin given in chronic immune thrombocytopenic purpura. Lancet 1995; 346: 220-1
17. Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-9
18. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
19. Carter CJ, Kelton JF, Hirsh J, et al. Relationship between the haemorrhage and antithrombotic properties of low molecular weight heparins in rabbits. Blood 1982; 59: 1239-45
20. Matthiasson SE, Lindblad B, Stjernquist U, et al. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 1995; 25: 203-11
21. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20
22. Monreal M, Lafoz E, Urrutia A, et al. Effects of long-term therapy with either heparin or low molecular weight heparin on serum lipid levels. A prospective study. Haemostasis 1995; 25: 283-7
23. Shaughnessy SG, Young E, Deschamps P, et al. The effects of low molecular weight and standard heparins on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-73
24. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7